Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label single-arm study of CN401 in relapsed/refractory peripheral T-cell lymphoma and NK/T-cell lymphoma
CTR20211451Phase 2Active
- Sponsor
- Antengene
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenalisib in peripheral T-cell lymphoma (PTCL), natural killer/T-cell lymphoma (NKTL), sponsored by Antengene. Started Aug 2021; status: active.
02
Drugs
tenalisib
03
Conditions
peripheral T-cell lymphoma (PTCL)natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on CTR20211451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211451.